Pharmavite, a nutrition-powered wellness company and maker of Nature Made vitamins, has acquired Bonafide Health, a women’s health company.
Through the acquisition of Bonafide Health, Pharmavite is expanding and complementing its existing women’s health business comprised of Uqora, a cutting-edge urinary tract health brand, and Equelle, "the only supplement with S-equol that is clinically shown to naturally address the root cause of symptoms related to estrogen decline," Pharmavite said.
“We’re thrilled to welcome Bonafide Health to Pharmavite. This acquisition positions us as the nation’s leading women’s health nutraceutical company, signaling a new era of innovation and science-based solutions in this underserved space,” said Jeff Boutelle, CEO of Pharmavite. “Bonafide’s unwavering commitment to research, development and robust scientific evidence mirrors Pharmavite’s rigorous standards, while its deep relationship with healthcare professionals aligns with our goal of ensuring nutrition education is at the forefront of the industry.”
[Read More: Pharmavite acquires urinary health brand Uqora]
“Our steadfast commitment to science and innovation has allowed us to build something special at Bonafide Health and we’ve been looking for the right partner to grow the business and reach more women that need support. Pharmavite is that partner,” said Michael Satow, co-founder and CEO of Bonafide Health. “Pharmavite deeply understands the importance of the model we’ve built, from the rigorous scientific data that underpins our products, to the power of the work we do with the doctors and other healthcare providers who are having conversations with women across the country looking for better solutions.”
Bonafide will continue to operate out of its current headquarters in Harrison, N.Y., and there are no workforce implications to the acquisition, the company said. Other commercial terms of the deal remain undisclosed.
Pharmavite was advised by Houlihan Lokey. William Hood & Company served as lead financial advisor and Evolution Life Science Partners served as co-advisor to Bonafide Health in the transaction.